Skip to main content


14-09-2017 | Melanoma | News | Article

ESMO 2017

Adjuvant nivolumab improves RFS over ipilimumab in metastatic melanoma patients

Patients with resected stage IIIB–IV melanoma derive a significant recurrence-free survival benefit from adjuvant treatment with nivolumab versus ipilimumab, interim results from the CheckMate 238 trial indicate.


N Engl J Med 2017; Advance online publication

11-09-2017 | Melanoma | News | Article

ESMO 2017

Dabrafenib plus trametinib cuts melanoma relapse risk significantly

Adjuvant combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib halves the risk for relapse in patients with stage III melanoma with BRAF V600E or V600K mutations, show results from the COMBI-AD trial.


N Engl J Med 2017; Advance online publication

30-08-2017 | Melanoma | News | Article

Pembrolizumab survival benefits confirmed for advanced melanoma

The final analysis of the phase III KEYNOTE-006 study shows continued survival benefits with pembrolizumab versus ipilimumab in patients with advanced melanoma.


Lancet 2017; Advance online publication

16-08-2017 | Melanoma | News | Article

Editor's pick

Final BRIM-3 data confirm vemurafenib survival benefit over dacarbazine

Final data from the BRIM-3 trial show that overall survival remains significantly better with vemurafenib than with dacarbazine when given to treatment-naïve patients with BRAFV600 mutation–positive metastatic melanoma.


Ann Oncol 2017; Advance online publication

04-08-2017 | Melanoma | News | Article

News in brief

Concurrent multisite radiotherapy, immunotherapy shows metastatic melanoma potential

Early results suggest that combining multisite radiotherapy with immune checkpoint inhibitor therapy can lead to positive outcomes in patients with metastatic melanoma without adding to the toxicity burden.

17-07-2017 | Melanoma | News | Article

Editor's pick

Mid-spectrum melanoma diagnoses have low reproducibility, accuracy

A study of US pathologists highlights the difficulties of diagnosing melanocytic skin lesions, finding low levels of intra- and interobserver reproducibility and accuracy in diagnoses ranging from moderately dysplastic nevi to early-stage invasive melanoma.


BMJ 2017; 357: j2813

image credits